DexCom Inc. (NASDAQ: DXCM) announced plans to add two independent directors to its board and expand a committee's oversight responsibilities following discussions with Elliott Investment Management.

The medical device company said it will appoint two new independent board members with medical technology leadership or lean operations experience. The appointments will bring the total number of new independent directors added since early 2023 to six.

Dexcom also said its existing Technology Committee will be renamed the Operations and Innovation Committee with an expanded mandate to oversee operations, quality and the company's technical roadmap in addition to its previous responsibilities.

The governance changes follow what Dexcom described as "constructive engagement" with Elliott Management. Marc Steinberg, a partner at Elliott, said in a statement that the investment firm sees potential for sustained double-digit growth and margin expansion at Dexcom.

"We are one of Dexcom's largest investors because of our conviction that the CGM market remains meaningfully underpenetrated," Steinberg said, referring to continuous glucose monitoring devices.

The announcement coincided with Dexcom's 2026 Investor Day presentation, where the company outlined its strategic and financial vision. CEO Jake Leach said the board enhancements align with the company's focus on quality and customer experience.

Dexcom develops continuous glucose monitoring systems primarily for diabetes management. The San Diego-based company was founded in 1999 and has operated in the glucose biosensing market for more than 25 years.